4578   Otsuka Holdings Co.,Ltd.

04/16/2025 15:30	Notification of Completion of Share Repurchase and Number of Treasury Stock to be Cancelled
04/15/2025 13:00	[Delayed] Corporate Governance Report
04/01/2025 15:30	Notice Regarding the Status of Share Repurchases
03/31/2025 08:00	Otsuka Files Biologics License Application (BLA) for Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy
03/28/2025 15:30	Notice Concerning Disposal of Treasury Shares as Restricted Stock Compensation
03/24/2025 15:30	Partial Correction to the Taiho Pharmaceutical to Acquire Next-Generation ADC Drug Discovery Company Araris Biotech
03/21/2025 16:30	Notice Regarding Change in Major Shareholders
03/19/2025 10:00	Notification of Completion of Share Repurchase Through Off-Auction Own Share Repurchase Trading System (ToSTNeT-3)
03/18/2025 16:30	Notice Regarding Share Repurchase Through Off-Auction Own Share Repurchase Trading System (ToSTNeT-3)
03/18/2025 16:30	Notice Regarding Share Repurchase and Cancellation of Treasury Stock
03/17/2025 17:00	Taiho Pharmaceutical to Acquire Next-Generation ADC Drug Discovery Company Araris Biotech
02/27/2025 08:00	Notice of the 17th Annual Shareholders Meeting and Meeting Materials(for FY2024)
02/14/2025 13:30	Approach and Policy on Reduction of Investment Units
02/14/2025 13:30	Consolidated Financial Results for the Fiscal Year Ended December 31, 2024 [IFRS]
02/07/2025 16:00	Notice Regarding Revisions of Consolidated Results Forecast for FY2024
01/10/2025 10:15	Otsuka Announces FDA Plans to Host an Advisory Committee Meeting to Discuss the sNDA for Brexpiprazole for the Treatment of Adults with PTSD
11/26/2024 15:30	Notification of Completion of Share Repurchase and Number of Treasury Stock to be Cancelled
11/13/2024 08:00	Otsuka Pharmaceutical Factory, Inc. and ICU Medical Announce the Establishment of Joint Venture
11/01/2024 15:00	Notice Regarding the Status of Share Repurchases
10/31/2024 13:30	Changes of Representative Director
10/31/2024 13:30	Consolidated Financial Results for the Nine-Month Period Ended September 30, 2024 [IFRS]
10/22/2024 16:00	Otsuka Announces Positive Interim Results from the Phase 3 Trial of Sibeprenlimab for the Treatment of Immunoglobulin A Nephropathy in Adults
10/01/2024 15:00	Notice Regarding the Status of Share Repurchases
09/25/2024 15:00	Notice Regarding Change in Major Shareholders
09/24/2024 15:00	Otsuka Obtains Additional Indication for Rexulti in Japan as an Adjunctive Treatment for Agitation Associated with Dementia due to Alzheimer's Disease
09/02/2024 15:00	Notice Regarding the Status of Share Repurchases
08/01/2024 13:00	Otsuka Pharmaceutical to Acquire Jnana Therapeutics Inc.
08/01/2024 08:00	Consolidated Financial Results for the Six-Month Period Ended June 30, 2024 [IFRS]
08/01/2024 08:00	Notice Regarding Share Repurchase and Cancellation of Treasury Stock
07/26/2024 15:00	Notice Regarding Revisions of Consolidated Results Forecast for the first half of FY2024
07/05/2024 17:00	Corporate Governance Report 2024/07/05
06/25/2024 15:00	Otsuka and Lundbeck announce FDA acceptance of sNDA filing for brexpiprazole in combination with sertraline for the treatment of adults with PTSD
06/07/2024 13:00	Otsuka Announces the 4th Medium-Term Management Plan
05/29/2024 08:00	Otsuka and Lundbeck Present Results from Three Clinical Trials of Brexpiprazole in Combination with Sertraline for the Treatment of PTSD in Adults
05/22/2024 17:00	Notice Regarding Revisions of Consolidated Results for the first half of FY2024 and Impairment Loss for intangible assets
05/22/2024 17:00	Otsuka to Terminate Development of AVP-786
04/30/2024 13:30	Consolidated Financial Results for the First Quarter of the Fiscal Year Ending December 31, 2024[IFRS]
04/26/2024 16:00	Notice Concerning Completion of Payment for Disposal of Treasury Shares as Restricted Stock Compensation
04/23/2024 08:30	[Delayed]Corporate Governance Report